BioSpace News Archive

Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders

ALKERMES Inspiration Grants® Program Will Award Up to $1 Million for the Development or Expansion of Innovative Programs

September 5, 2018
·
5 min read
Pharm Country

Headaches Associated With Commuting, Dating And Even Adulting? Now, There’s An Excedrin® For That

Excedrin® Launches Limited Editions Targeting Today’s Top Headache-Inducing Moments

September 5, 2018
·
4 min read
Correvio Reports Preliminary Data Collected from Brinavess Treatment Episodes in EU Post-Authorization Safety Study

Zero Deaths Reported, Safety Outcomes of Interest Observed in 0.8% Cases

September 5, 2018
·
9 min read
Pharm Country

Bristol-Myers Squibb Kicks Off Coast 2 Coast 4 Cancer Ride to Fundraise for the V Foundation for Cancer Research

More than 100 company employees will ride across the country with the goal of raising $1 million for cancer research

September 5, 2018
·
4 min read
Business

Antibe Therapeutics Announces Strategic Licensing Deal for Lead Drug in South Korea

License includes C$13 million in non-dilutive milestone payments and a double-digit royalty to Antibe

September 5, 2018
·
4 min read
Biotech Bay

Veeva Vault Submissions Publishing Now Available to Help Accelerate Submission Delivery

Seamlessly incorporate publishing activities within Veeva Vault RIM for end-to-end submission development

September 5, 2018
·
4 min read
Business

Stellar Biotechnologies to Supply KLH to National Institutes of Health

Initiated product manufacturing for the NIH’s National Cancer Institute, which plans to use a vialed formulation of Stellar KLH in dendritic cell-based cancer therapies.

September 5, 2018
·
4 min read
Business

Provention Bio Appoints Accomplished Biotech Executive, Chip Catlin, to its Board of Directors

Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the appointment of Avery (Chip) W. Catlin, a seasoned and accomplished corporate financial executive, to its Board of Directors.

September 5, 2018
·
5 min read
Drug Development

Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program

Plans to initiate a global, pivotal, single-arm Phase 3 trial in treatment-naïve PNH patients

September 5, 2018
·
4 min read
Biotech Beach

TP Therapeutics Announces Updated Interim Phase 1 Data with Repotrectinib (TPX-0005) in ROS1 Fusion-positive NSCLC to be Presented at World Conference on Lung Cancer

Preclinical and early clinical findings have shown Repotrectinib to be a potent and selective inhibitor for ALK, ROS1, and TRK family.

September 5, 2018
·
3 min read